Protagonist Therapeutics - Biotech Company in the Crosshairs of Johnson & Johnson!
Reading Time: 1 minute
Business Driver: Protagonist Therapeutics (PTGS) specializes in the development of peptide-based therapeutics, focusing on new approaches to treat inflammatory diseases and blood disorders. Among other things, the company has several drugs in the third phase of clinical trials including Rusfertide (Polycythemia Vera), while collaborating with Johnson & Johnson on Icotronkinra (Psoriasis/Ulcerative Colitis). On October 10, the "Wall Street Journal" reported that Johnson & Johnson is negotiating a takeover of Protagonist Therapeutics. ...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
